Stroke Trials Registry

AICLA
Controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

Principal Investigator
MG Bousser

Study Size Actual:

604

Status:
Trial complete. Results published 1/83.

Purpose:
To determine whether aspirin or aspirin + dipyridamole would produce a significant reduction in the subsequent occurrence of fatal and nonfatal cerebral infarction.

Interventions:

Aspirin (stroke prevention)
Antiplatelet agent; inhibits thromboxane A2

Dipyridamole
Platelet aggregation inhibitor

Year Published: 1983

Design:
Randomized, double-blind, placebo-controlled trial of 604 patients.

Inclusion Criteria
Atherothrombotic cerebral ischemic event (transient or completed) referable either to the carotid or to the vertebral-basilar circulation.

Patient Involvement:
Patients were randomized into one of three groups: A-aspirin (1 g/day); AD-aspirin (1 g/day) + dipyridamole (225 mg/day); P-placebo. Follow-up period of 3 years.

Primary Outcome:
Recurrence of fatal or nonfatal cerebral infarction within 3 years.

Results:
The number of fatal and nonfatal cerebral infarctions was 31 in the placebo (P) group, 17 in the A group and 18 in the AD group. Groups A and AD, taken together, had a significantly lower rate of stroke recurrence compared to the placebo group. There was no difference between groups A and AD.

Source of Information:
Stroke 1983 Jan-Feb;14(1):5-14.

Web Links and Publications:

The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results.
Rev Neurol (Paris) 1983;139(5):335-48.

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.
Stroke 1983 Jan-Feb;14(1):5-14.

Controlled cooperative trial. Secondary prevention of atherosclerosis-related cerebral ischemic accidents by aspirin dipyridamole. 2: Description of subjects at the beginning of the trial.
Rev Neurol (Paris) 1982;138(1):1-15.

This information last updated on: 2/22/2001

UID: 235